Latest Breaking News On - Pulmonary fibrosis treatment - Page 1 : comparemela.com

The overall market of idiopathic pulmonary fibrosis is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging therapy for idiopathic pulmonary fibrosis treatment, will boost the idiopathic pulmonary fibrosis market in the forecasted period (2023–2032).New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) |

United kingdomUnited statesNew yorkBristol myers squibbMark biosciencesVicore pharmaNitto denkoGuangdong raynoventAvalyn pharmaGilead sciencesBoehringer ingelheimHealthcare servicesKadmon corporation llcsAlgernon pharmaceuticalsAvalyn pharmaceuticalsNitto denko corporation